EFFECT OF EUDRAGITÂ® POLYMERS (RS 100 AND RL100) ON THE RELEASE OF DICLOFENAC SODIUM FROM MICROCAPSULES
*Sonika Rani Jangra and D.C. Bhatt
The controlled release dosage forms have made significant progress in terms of clinical efficacy and patient compliance. The micro-encapsulation is one of the widely accepted technique for the controlled drug delivery. Polymers used as in formulation play a vital role in controlling the drug release from the microcapsules. Diclofenac Sodium, is a widely used nonsteroidal anti-inflammatory drug (NSAID) taken or applied to reduce inflammation or for reducing pain in certain conditions. It is used commonly to treat mild to moderate postoperative or post traumatic pain, when inflammation is present. Diclofenac Sodium is BCS class II drug and it was microcapsulated by the solvent evaporation technique using a nonaqueous solution of polymers EudragitÂ® RS100 and EudragitÂ® RL100 to achieve its sustained release from the microcapsules at a slower rate. The effect of two copolymers EudragitÂ® RS100 and EudragitÂ® RL100 was investigated using various drug polymer ratio. These microcapsules were free-flowing in nature with smooth surface, spherical shape as examined by scanning electron microscopy. The data obtained from in vitro dissolution profiles of drug formulations were compared using different release kinetics models and the regression coefficients were compared.
Keywords: Microencapsulation, Eudragit, Sustained Release, Diclofenac Sodium.
[Full Text Article]